Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines Press release
Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis Press release
EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology Press release
Galderma launches advanced new serum with ALASTIN Skincare® - C-RADICAL Defense Antioxidant Serum Press release
Powered by Peptides: Galderma introduces Cetaphil Healthy Renew, a retinol alternative skincare range Press release
Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement Press release
